Blood Marker and Quality of Life in Chronic Intestinal Blood Flow Problems
Compares a blood marker in adults with chronic bowel blood flow problems to other people.
Plain-language title generated from the registry record
Registry title: Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia
Key facts
- Where
- Oslo, NorwaySee the site
Where in Norway
- Department of vascular surgery, Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT06468774
- Record updated
- 30 July 2025
- Original description
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals.Read full original descriptionShow less
Intestinal Ischemia Biomarker and Quality of Life of the Patients With Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome
Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals.
This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals.
Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.
Inclusion: For the patient groups :; Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment; Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment; For the control group:; Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy; Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound; Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound.
Exclusion: -.